DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 216 filers reported holding DENALI THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $249,231 | -26.2% | 12,081 | +5.5% | 0.00% | – |
Q2 2023 | $337,919 | +25.2% | 11,451 | -2.3% | 0.00% | – |
Q1 2023 | $269,983 | -26.8% | 11,718 | -11.6% | 0.00% | – |
Q4 2022 | $368,649 | +3.3% | 13,256 | +14.0% | 0.00% | – |
Q3 2022 | $357,000 | +11.6% | 11,625 | +6.8% | 0.00% | – |
Q2 2022 | $320,000 | +23.6% | 10,883 | 0.0% | 0.00% | – |
Q1 2022 | $259,000 | -51.9% | 10,883 | -9.9% | 0.00% | – |
Q4 2021 | $539,000 | -50.8% | 12,081 | -44.3% | 0.00% | -100.0% |
Q3 2021 | $1,095,000 | -66.9% | 21,708 | -48.5% | 0.00% | -66.7% |
Q2 2021 | $3,304,000 | +50.9% | 42,121 | +9.8% | 0.00% | +50.0% |
Q1 2021 | $2,190,000 | +40.8% | 38,355 | +106.6% | 0.00% | 0.0% |
Q4 2020 | $1,555,000 | +247.9% | 18,567 | +48.9% | 0.00% | +100.0% |
Q3 2020 | $447,000 | +40.6% | 12,468 | -5.1% | 0.00% | – |
Q2 2020 | $318,000 | -33.5% | 13,139 | -51.8% | 0.00% | – |
Q1 2020 | $478,000 | +101.7% | 27,246 | +100.5% | 0.00% | – |
Q4 2019 | $237,000 | +0.4% | 13,587 | -12.0% | 0.00% | – |
Q3 2019 | $236,000 | – | 15,435 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |